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Background: Myostatin, a member of the TGFβ superfamily, is well known as a potent and specific negative
regulator of muscle growth. Targeting the myostatin signalling pathway may offer promising therapeutic strategies
for the treatment of muscle-wasting disorders. In the last decade, various myostatin-binding proteins have been
identified to be able to inhibit myostatin activity. One of these is GASP1 (Growth and Differentiation
Factor-Associated Serum Protein-1), a protein containing a follistatin domain as well as multiple domains associated
with protease inhibitors. Despite in vitro data, remarkably little is known about in vivo functions of Gasp1. To further
address the role of GASP1 during mouse development and in adulthood, we generated a gain-of-function
transgenic mouse model that overexpresses Gasp1 under transcriptional control of the human cytomegalovirus
immediate-early promoter/enhancer.
Results: Overexpression of Gasp1 led to an increase in muscle mass observed not before day 15 of postnatal life.
The surGasp1 transgenic mice did not display any other gross abnormality. Histological and morphometric analysis
of surGasp1 rectus femoris muscles revealed an increase in myofiber size without a corresponding increase in
myofiber number. Fiber-type distribution was unaltered. Interestingly, we do not detect a change in total fat mass
and lean mass. These results differ from those for myostatin knockout mice, transgenic mice overexpressing the
myostatin propeptide or follistatin which exhibit both muscle hypertrophy and hyperplasia, and show minimal fat
deposition.
Conclusions: Altogether, our data give new insight into the in vivo functions of Gasp1. As an extracellular
regulatory factor in the myostatin signalling pathway, additional studies on GASP1 and its homolog GASP2 are
required to elucidate the crosstalk between the different intrinsic inhibitors of the myostatin.Background
Improving muscle mass and function is of a considerable
clinical interest in therapeutic strategies for musculo-
skeletal disorders and has been assessed by several stud-
ies [1-3]. In the last decade, among all these approaches,
dramatic attention has been focused on the regulation of
the myostatin (GDF8) pathway. Indeed, myostatin is a
key regulator of skeletal muscle growth and homeostasis.
In mice, targeted inactivation of the Gdf8 gene causes a
large and widespread increase in skeletal muscle mass,
resulting from a combination of muscle cell hyperplasia* Correspondence: veronique.blanquet@unilim.fr
1INRA, UMR1061 Unité de Génétique Moléculaire Animale, Limoges 87060,
France
2Université de Limoges, Limoges 87060, France
Full list of author information is available at the end of the article
© 2012 Monestier et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand hypertrophy. Moreover, postnatal inhibition of
myostatin signalling, through the delivery of neutralizing
antibodies, myostatin propeptide injection or antisense
RNA showed skeletal muscle improvement when admi-
nistered to mice of different ages [4-12]. The identifica-
tion of myostatin-binding proteins capable of regulating
myostatin activity further expanded the number of po-
tential therapeutic targets [13]. Thus, follistatin (FS) can
function as a potent myostatin antagonist, its overex-
pression in mice is found to enhance muscle growth
[13,14]. The increase in muscle mass observed in trans-
genic mice overexpressing FS in muscle is even signifi-
cantly larger than that observed in Gdf8-/- mice [15].
However, follistatin is not a specific inhibitor for myosta-
tin and binds also to other TGFβ including activin. In
addition to follistatin, two other proteins have beenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Generation of the surGasp1 transgenic mice.
A) Schematic illustration of the surGasp1 transgene construct. To
generate transgenic mice, a 3578 bp SalI-NsiI fragment comprising
the Gasp1 coding sequence under the CMV promoter was injected
into pronucleus of the one cell mouse embryo. S:SalI ; N:NsiI. B)
Quantitative PCR analysis of Gasp1 expression on muscle (light grey)
and brain (dark grey) samples from F1 mice of the six independent
transgenic lines generated.
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tatin. Follistatin-related gene is highly similar to follistatin
and has also been shown to inhibit activin and multiple
bone morphogenic proteins in vitro [16]. Growth and dif-
ferentiation factor-associated serum protein-1 (GASP1;
also called WFIKKN2) is a secreted protein that contains
multiple domains associated with protease-inhibitory pro-
teins including a whey acidic protein domain, a Kazal do-
main, two Kunitz domains, and a netrin domain. It also
contains a highly conserved module of cysteine-rich se-
quence termed the follistatin domain. GASP1 was shown
to bind directly but independently to both mature myosta-
tin and the myostatin propeptide and to inhibit myostatin
activity but not that of activin or TGFβ1 in vitro [17]. Like
its homologous protein GASP2, GASP1 also has a high af-
finity for GDF11, a secreted factor that regulates anterior/
posterior patterning in the axial skeleton [18]. Recent
studies showed that both GASP1 and GASP2 bind growth
factors TGFβ1, BMP2 and BMP4 but do not inhibit
in vitro their signalling activity [19]. GASP1 and 2 show
distinct expression patterns both in the developing fetus
and the adult. In the developing fetus, GASP1 expression
is highest in the brain, skeletal muscle, thymus and kidney
while GASP2 is abundant in the lung, skeletal muscle and
liver [20]. In the adult, GASP1 is primarily expressed in
the ovary, testis, and brain while GASP2 is in the pan-
creas, liver, and thymus [20]. To date, despite these data,
little is known about the precise in vivo functions and pro-
tein interactions of these GASP proteins. To highlight the
range and extent of Gasp1 roles during mouse develop-
ment and in adulthood, we have generated and character-
ized transgenic mouse lines that ubiquitously overexpress
Gasp1 under the control of a cytomegalovirus (CMV)
promoter. Six transgenic lines have been isolated and two
were selected with different levels of overexpression of
Gasp1 in muscle, brain, heart, spleen, liver, lung and kid-
ney for analyses. Detailed phenotypic characterization
shows muscle abnormalities but no obvious defects in
other major organ systems.
Results
Generation of Gasp1 transgenic mice
With the purpose of developing transgenic mice with
constitutive expression of Gasp1, the cDNA was cloned
into a vector containing a CMV promoter. The trans-
gene was liberated from the vector backbone by the
enzymes SalI and NsiI as shown in Figure 1A and was
purified for microinjection. After reimplantation of the
manipulated embryos, pups were screened for the pres-
ence of the transgene by PCR analyses of genomic DNA
from tail clips to identify those harboring the transgene
DNA. Six of the 39 offspring carried the transgene con-
struct in the genome. Breeding lines were successfully
established from all 6 founders by crossing them with anon-transgenic mouse. These lines were designated sur-
Gasp1-01, surGasp1-03, surGasp1-06, surGasp1-08,
surGasp1-20 and surGasp1-33. Analysis of the F1 off-
spring showed that the transgene was for each line
transmitted to ~ 50% of the litter as expected for Men-
delian inheritance. Quantitative polymerase chain reac-
tion was performed to determine Gasp1 mRNA levels
from muscle and brain of F1 animals (Figure 1B). As
predicted, expression levels varied depending of the
transgenic strain. We opted to pursue further phenotyp-
ical analyses on the two lines surGasp1-20 and
surGasp1-06 because of their high Gasp1 expression
levels in both tissues. For each line, heterozygous male
and female mice were crossed to produce F2 mice.
About 75% of the F2 offspring carried the transgene. To
determine their precise genotype, heterozygote or homo-
zygote, and to estimate the integrated transgene copy
number, semi quantitative real time PCR was performed
as shown in Figure 2. The homozygous surGasp1-20






















Figure 2 Semi quantitative real-time PCR based genotyping.
The graph represents the genotyping of F2 surGasp1-20 or
surGasp1-06 mice. The abscissa shows the relative quantification of
Gasp1, the ordinate corresponds to the CMV relative quantification.
Animals can be divided in 3 groups according to their CMV and
Gasp1 DNA copy number: wildtype animals [triangle, (n = 3)]
are characterized by no amplification of the CMV sequence,
heterozygous mice [rhombus, (n = 8)] have the same CMV or Gasp1
copy number as the F1 animals used as calibrator, and homozygous
mice [square, (n = 8)] have twice as many CMV and Gasp1 copies
as F1 animals.
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was stable within all subsequent generations.
Tissue-specific expression
In order to determine the tissue distribution of the trans-
gene expression and its level, total RNA was isolated from
multiple tissues from the offspring of the surGasp1-20
and surGasp1-06 breeder lines and was subjected to quan-
titative RT-PCR amplification. As shown in Figure 3, the
surGasp1-20 line had the highest expression (50 to 10000
fold compared to wild-type FVB/N) in all tested organs
with a very high increase in kidney. Although surGasp1-
06 transgenic mice carried more copies of the transgene,
they displayed a much lower Gasp1 RNA expression level
with no significant overexpression in kidney and lung.
Western blot analysis of GASP1 expression in various tis-
sues was performed using three different antibodies. We
detected its expression in all surGasp1-20 tested tissues
and only in the pancreas of wild-type animals (Figure 3B).
No positive signal was revealed in the other tissues of
wild-type or surGasp1-06 mice, most probably because of
the low level of expression of the protein or the potential
lack of sensitivity of our western analysis.
Transgenic mice are characterized by an increase in
muscle mass
Immediately after birth, the transgenic mice appeared
normal. However, within 2 weeks after birth, homozy-
gotes surGasp1-20 mice showed a significant increase in
body weight of about 4.5 grams compared to wildtypelittermate mice (Figure 4). Such a difference was also
detected in older mice (12-16 weeks old). A similar but
milder phenotype was also observed in the surGasp1-06
line (data not shown). From 8 weeks old, mice overex-
pressing Gasp1 showed a hypertrophic skeletal muscle
phenotype (Figure 5A-J). Increased muscle mass was also
evident when we compared the wet weights of the gastro-
cnemius, rectus femoris and pectoralis major muscle
groups of heterozygous or homozygous surGasp1-20 mice
with those of the wild-type mice (Figure 5K). Similar
results were observed for surGasp1-06 muscles (data not
shown). The increases were found in both sexes with a
muscle weight gain of 35% for the gastrocnemius and rec-
tus femoris, and 45% for the pectoralis major muscles
from homozygous surGasp1-20 mice. The magnitude of
these increases was correlated with the muscle expression
level of the transgene. Surprisingly, no significant defect
in the development of the other tested major organs
(brain, heart, kidney, liver, spleen) was detected (data not
shown).
Effect of the overexpression of GASP1 on body
composition
To determine the origin of increased body weight in sur-
Gasp1 mice, analysis of body composition by EchoMRI-
500™ was performed allowing us to measure whole body
fat mass, lean tissue mass, free water, and total body
water in live animals without the need for anesthesia or
sedation. This study revealed no change in total fat mass
and lean mass in surGasp1-20 mice. It contrasts with
data obtained with constitutive myostatin deficient mice
which present a reduction in fat mass (Figure 6).
The increase in muscle mass results from hypertrophy
rather than hyperplasia
To determine whether the increase in muscle mass
resulted from a combination of increased fiber numbers
and increased fiber sizes, we performed histological and
morphometric analysis of the rectus femoris muscles
from wild-type (n = 3, 600 fibers per animal) and homo-
zygotes surGasp1-20 mice (n = 3, 300 fibers per animal).
Cryostat sections of muscles stained by hematoxylin-
eosin or Gomori’s silver impregnation indicated a sub-
stantial increase (36% on average) in the fiber diameter
of the transgenic mice (Figure 7A-D, G). Fiber typing
was performed using the myosin ATPase method allow-
ing differentiating 3 fiber types: I, IIA and IIB [21]. All
muscle fiber types increased in diameter in the trans-
genic lines (Figure 7E, F, H and data not shown). The
relative proportion of type I, II myofibers in wild-type,
surGasp1-06 and surGasp1-20 rectus femoris muscle did
not change significantly (Additional file 1). Furthermore,
no difference was found in the total number of muscle
fibers per cross-sections. These results suggested that
AB
Figure 3 Relative expression levels of Gasp1 RNAs in mouse tissues. A) mRNA expression levels were determined by qRT–PCR relative to the
reference genes Gapdh, TfIID in extracts from 7 different mouse tissues from wild-type (grey, n = 4), surGasp1-20 (light grey, n = 4), surGasp1-06
(dark grey, n = 4) animals. The horizontal dashed line represents a twofold increase in expression level. Mean values of three separate data
acquisitions per tissue sample are shown. Data are expressed as mean +/- SEM. B) Western blot analysis of GASP1 expression in surGasp1
transgenic mice: total proteins were extracted from spleen, kidney, liver, heart, pancreas, brain and some skeletal muscles dissected from
12-week-old mice. GASP1 was detected using a polyclonal goat anti-GASP1. Secondary HRP-anti-goat IgG was used for signal visualization with
chemiluminescence. GAPDH was used as a loading control. The two protein bands (bottom panel) probably represent different glycosylation
states of GASP1.
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than hyperplasia.
Discussion
Intensive efforts have been made over the last decade to
explore the molecular mechanisms underlying the regu-
lation and function of myostatin, a key negative regula-
tor of skeletal muscle growth. The identification of
several components of the myostatin-signalling pathway
had important implications with respect for testing the
therapeutic value of a myostatin antagonist in muscle
wasting disorders such as Duchenne muscular dystrophy
[22,23] cachexia and age-related sarcopenia [24-26].
Among the known myostatin-binding proteins, GASP1
has been shown to inhibit myostatin activity in vitro andmay maintain myostatin latency but no data was avail-
able on the effect of GASP1 when expressed as a trans-
gene in all skeletal muscles of wild type mice. In the
present study, we have generated a “gain of function”
mouse model to further understand the in vivo roles of
Gasp1. These mice carry a transgene containing the
Gasp1 coding sequence under the transcriptional regula-
tion of the ubiquitous CMV promoter. As a conse-
quence, Gasp1 mRNA expression is greatly enhanced in
several organs including muscle, brain, spleen, liver,
heart, lung and kidney. Analysis of the two Gasp1 trans-
genic lines with the highest transgene expression
revealed a skeletal muscle hypertrophic phenotype. This
might have been expected based on previous data indi-






















Figure 4 Body weight of surGasp1 mice. Body weight of wild
type (dark grey, n = 40) and surGasp1-20 homozygous mice (light
grey, n = 31) were measured from 3 to 12 weeks old. Data were
expressed as mean +/- SD.
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gene protein whose overexpression leads to an increase
of the muscle mass. Furthermore, viral delivery of a
Gasp1 expression cassette into adult muscle has been
shown to induce increases in muscle mass and grip
strength [13]. The surGasp1 mice have similar average
life span compared to standard inbred laboratory mice
(http://research.jax.org/faculty/harrison/ger1vi_Lifespan.
html) Except the phenotype described in this paper, no
other gross abnormalities were noted, even in elder sur-
Gasp1 mice (≈ 28 months). Effects of elevated GASP1
on body growth were not observed before day 15 of
postnatal life. The enhanced muscle growth occurs in
both male and female animals with a more pronounced
phenotype in male pectoralis major muscle. The individ-
ual weights of the gastrocnemius, rectus femoris and pec-
toralis major muscles were increased. The masses of
other skeletal muscles were also increased. The sizes of
other internal organs did not differ from those of control
mice despite overexpression of GASP1. Unlike the
myostatin-deficient animals or FS overexpressing mice,
which exhibit both muscle hypertrophy and hyperplasia,
we only observed an increase in myofiber size without a
corresponding increase in myofiber number in surGasp1
animals. As the number of myofibers in muscle is largely
determined during prenatal development, the overex-
pression of Gasp1 does not seem to provide prenatal ef-
fect. However, we cannot preclude that the lack of
hyperplasia is not the result of a too moderate expres-
sion of the transgene during embryonic and fetal stages,
although Gasp1 is strongly expressed in postnatal 3 days
mice (Additional file 2). In the litterature, heterozygous
mutations in the myostatin gene or surexpression of its
propeptide have been reported to result also inhypertrophy and no hyperplasia [27]. Taken together,
these results may be reflective of an incomplete inhib-
ition of the myostatin. Moreover, Zhu et al. [28] have
described that mice carrying a dominant negative form
of myostatin preventing the release of the mature myos-
tatin from the propeptide exhibited a significant increase
in muscle mass that resulted from myofiber hypertrophy
and not from myofiber hyperplasia. As Hill et al. [17]
suggested, GASP1 may inhibit the propeptide proteolysis
to keep the myostatin in a latent and inactive form. Such
possible mechanism may explain the observed pheno-
type in the surGasp1 mice.
The body weight increment in surGasp1 mice is visible
at 3 weeks of age. However, during animal growth, the
body weight difference between wild-type and transgenic
mice does not increase, indicating that the effect of
Gasp1 overexpression may arise during the first 21 days
of life, probably by satellite cells activity or AKT/FOXO
dependent signalling pathway . To gain insights into the
molecular mechanism, we performed an expression array
analysis of 91 genes involved in muscle development.
From those, only 5 genes Ccnd1 (cyclin D1), Actvr1c
(Alk7), Myh3, Myod1 and Pparγ were slightly down- or
up-regulated in the surGasp1 mice (Figure 8, Additional
file 3: Table 1). Cyclin D1, an important component of
the cell cycle machinery has been shown to be a major
intracellular target for myostatin during myostatin-
induced G1 cell cycle arrest and proliferation inhibition
[29]. Ji et al. [30] showed that myostatin blocked the re-
cruitment of p300 to the cyclin D1 promoter, resulting in
the silencing of cyclin D1 gene expression. The increase
of Ccnd1 expression level in the surGasp1 mice is in ac-
cordance with those previous studies. The analysis of the
Gasp1 promoter revealed the presence of four PPARγ
binding sites. A negative feedback loop may exist and
could explain the down-regulation of Pparγ in the mu-
tant mice. Finally, most of the observed variations are
related to an activation of the canonical Wnt/β-catenin
signalling pathway and are consistent with observations
in GDF8-null mice [31]. The mRNA expression levels of
Pax3 and Pax7 genes which are expressed by postnatal
satellite cells [32] or members of AKT/FOXO pathway
remained unchanged in surGasp1 mice when compared
to wildtype. However, the activation or repression of this
pathway is essentially due to postranslational modifica-
tion. Further studies are needed to understand the rele-
vance of the AKT/FOXO signalling in the surGasp1
phenotype.
In mammals, myofibers are mainly classified into
glycolytic and oxidative fibers based on their metabolic
profiles. In mice, fast glycolytic fibers express the type
IIB MHC isoform whereas oxidative fibers express type I
(slow fibers), the fibers expressing MHC IIA are capable
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Figure 5 Effects of Gasp1 overexpression in skeletal muscle. Increased skeletal muscle mass in surGasp1-06 [heterozygote (C, D),
homozygote (E, F)] mice or surGasp1-20 animals [heterozygote (G, H), homozygote (I, J)] compared to wildtype littermates (A, B). Top panels:
pectoral muscles; bottom panels: lower limb. (K) Muscle weight. Muscles of 12-week-old mice were carefully dissected and weighed. Wild-type
(dark grey) n = 36; heterozygotes surGasp1-20 (light grey) n = 27; homozygotes surGasp1-20 (grey) n = 18. Values are means ± SEM. * : p < 0.05;
** : p < 0.01; and *** : p < 0.001.
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change fiber type distribution while a lack of myostatin
results in an alteration in the fiber type composition
[33-36]. Glycolytic (phosphofructokinase, lactate dehydro-
genase) or oxidative (citrate synthase, isocitrate dehydro-
genase, cytochrome c-oxidase) enzyme activities did not
show any significant differences between wild-type and
surgasp1-20 mice, confirming the above mentioned result
(data not shown).
Interestingly, we do not detect a change in fat pad
mass in our Gasp1 transgenic mice. This result differs
from the results reported for the myostatin knockout
mice or transgenic mice overexpressing the myostatin
propeptide in which a reduction in adiposity is observed
[14,37,38]. Recent literature showed that myostatin in-
hibition in skeletal muscle, but not in adipose tissues, is
primarily responsible for a decrease of fat mass [39].This effect on fat pad could reflect a regulation of myos-
tatin independant from GASP1.
Conclusions
Taken together, our data provide definitive evidence of
the role of Gasp1 in vivo, in particular in muscle. In our
transgenic mice, estimation of the amount of GDF8 as-
sociating with GASP1 will be an important issue, thus
providing mechanistic insights into this association. We
are currently crossing our transgenic mice overexpres-
sing Gasp1 on the myostatin null background to investi-
gate if GASP1 stimulates muscle growth by additional
mechanisms independent of myostatin inhibition like it
has been shown in transgenic mice overexpressing follis-
tatin presenting a quadrupling of muscle mass [15]. The
related protein, GASP2 has also been shown to be cap-
able of binding myostatin although GASP2 was not
Figure 6 Body composition of surGasp1 mice. Proportion of
body fat and lean mass in surGasp1-20, wild-type FVB or Bl6/FVB,
myostastin deficient (Gdf8-/-) mice at 10 weeks was calculated as the
percentage of their respective body weights. Since the Gdf8-/- mice
were maintained on the Bl6/FVB background, we used wild-type
Bl6/FVB as control. Data are presented as means ± SEM. * : p < 0.05.
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myostatin in serum [17]. GASP2 appears to be similar to
GASP1 in its ability to bind GDF8 or GDF11 in vitro
but effects of GASP2 on other TGFβ ligands are not yet
known [18]. Further research will be required to deter-




All mice were bred and housed in the animal facility of
Limoges University under controlled specific pathogen
free conditions (21°C, 12-h light/12-h dark cycle) with
free access to standard mouse chow and tap water. All
of the experimental procedures were carried out in ac-
cordance with the local ethics commission.
Transgene construction and generation of transgenic
lines
First strand cDNA was synthesized from 1μg of total
muscle RNA using the SuperScript® III Reverse
Transcriptase (Invitrogen) with oligodT primers. The
coding sequence of murine Gasp-1 was PCR-amplified
from muscle cDNA using primers 50-ATGTGTGCCCC
AGGGTATCATCG-30 located at the position 159-
181 bp and 50-TCATTGCAAGCCCAGGAAGTCCT
T-30 located at the position 1851-1874 bp (trans-
cript sequence ENSEMBL ENSMUST00000061469).
The 1716 bp fragment (GenBank accession number:
JQ080910) was introduced into the expression vector
pcDNATM3.1/V5-His® TOPO (Invitrogen) to generatethe psurGasp1 vector. Consequently, Gasp1 is under the
human cytomegalovirus immediate-early promoter/en-
hancer leading to a strong constitutive expression. In
our construct, the GASP1 protein is not expressed as a
fusion to the V5 epitope and polyhistidine tag since a
stop codon is present at the 30 end of Gasp1
cDNA. A purified 3578 bp Sal1-NsiI fragment was
microinjected into the male pronucleus of one-cell
fertilized FVB/N embryos. Transgenic founders,
or surGasp1 animals were identified by PCR of tail-
extracted genomic DNA using primers fwdU2: 50-AAG
TACGCCCCCTATTGACG-30 and revR1: 50-CCAG
AGGTTGGGGTTCATGT-30. Founders bearing the
transgene were bred to wild-type FVB/N mice to gene-
rate F1 offspring. Transgenic F1 mice were bred with
other transgenic or wildtype FVB/N mice as necessary
to maintain and expand the colony.
Phenotyping of mice
Muscle weights were measured following dissection of
12-week-old mice. Individual muscles from both sides of
the animal were taken and the average weight was used
for each muscle. Body composition analysis to determine
fat and muscle contents was performed on conscious
mice at 10 weeks of age, using the EchoMRI-500™ whole
body composition analyzer (Echo Medical Systems).
Histological and morphometric analysis
Cryosections (14 μm) of rectus femoris muscles were pre-
pared from frozen muscles of wildtype or surGasp1 12-
week-old mice. Transverse sections were processed for
hematoxylin and eosin staining. For cross sectional area
measurement and fiber counting, muscles were stained
with a reticulin silver staining kit (04-040801, Bio-Optica
Milano S.p.A). Fiber typing was performed using the my-
osin ATPase method (pH 4.6) allowing differentiating 3
fiber types: I, IIA and IIB. For morphometric analysis, the
muscle fiber sizes were measured with Image J software.
Quantitative PCR
Total RNA was isolated from spleen, kidney, liver, heart,
lung, brain and skeletal muscles dissected from mice of
various ages (8 to 12 weeks, see figures legend) using
TRIzol (Invitrogen) according to the manufacturer’s in-
struction and relative RNA concentration was determined
by spectrophotometric analysis. 1.5 μg of total RNA was
reverse-transcribed into DNA using the high-capacity
cDNA reverse transcription kit (Applied Biosystems). Real-
time PCR was performed in triplicate using 50 ng of cDNA
for each sample. Relative amounts of transcripts were
determined using Taqman probes specific for Gasp1
(Mm00725281_m1), Gapdh (Mm99999915_g1), TfIID
(Mm00446973_m1) on an ABI PRISM© 7900 system (Ap-












































































Figure 7 Gasp1 overexpression induces a marked muscle fiber hypertrophy. Sections were prepared from rectus femoris muscles of
wild-type or surGasp1-20 mice and stained by hematoxylin-eosin (A, B), silver impregnation (C, D) or myosin ATPase stain with acidic
preincubation (E, F). (G) Overall muscle fiber cross-sectional area of wild-type or surGasp1-20 rectus femoris muscles. (H) Distribution of muscle




















Figure 8 Relative expression levels of genes involved in muscle
development in quadriceps surGasp1 mice. Using the TLDA
technology, mRNA expression levels were determined by qRT–PCR
relative to the reference genes Gapdh, TFIID, Dffa and fcgrt in
quadriceps from surGasp1-20 (dark grey, n = 4) and surGasp1-06 (light
grey, n = 4) animals. Calibration value: wild-type sample = 1.
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sample to the average change in cycle threshold value of
the controls. TLDA (Taqman low density array, Applied
Biosystems) assays were performed based on the same
above conditions, except 100 ng cDNA was used for each
fill reservoir. The selected target genes analysed are listed in
the Additional file 3: Table 1.Genotyping assay
SurGasp1 F1 animals were genotyped by checking the
presence of the CMV sequence using specific primers
(fwdU2: AAGTACGCCCCCTATTGACG and revR1:
CCAGAGGTTGGGGTTCATGT). These F1 animals are
used as calibrator in the next step of the qPCR assay, i.e.
their CMV or Gasp1 copy number is arbitrarily defined
as 1. Then, SYBR Green–based real-time PCR was carried
out by 3 amplifications for each sample (F2 mice) using
the ABI PRISM® 7900 system (Applied Biosystems). One
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AGCTT) and Gasp1-Rev (GAGATTGTGGTGGCAGTG
AC) primers was designed to yield a 148 bp product that
corresponds to Gasp1 exon 2, the second reaction, by
using CMV-Fwd (CCCACTTGGCAGTACATCAA) and
CMV-Rev (GCCAAGTAGGAAAGTCCCAT) primers,
was designed to yield a 123 bp product that corresponds
to the CMV promoter. The last reaction by using CCR5-
Fwd (GCACAAAGAGACTTGAGGCA) and CCR5-Rev
(GTCATCTCTAGGCCACAGCA) was designed to yield
a 81 bp product that corresponds to the CCR5 allele de-
fining our reference gene. All the tests were done in trip-
licate. Each reaction was carried out in 20 μl of reaction
mixture that contained SYBR® Green master mixture,
each of the forward and reverse primers at a final con-
centration of 300 nM, and 5 ng of purified DNA sample.
The thermal profile began with incubations at 50°C for 2
min and 95°C for 10 min followed by 40 cycles of ampli-
fication alternating between 95°C for 15 sec and 60°C for
1 min. The SYBR® Green fluorescent signal was obtained
once per cycle at the end of the extension step. After
amplification, melting curve analysis was performed by
heating the PCR products to 95°C for 15 sec, then cool-
ing it to 60°C for 15 sec, followed by a linear
temperature increase to 95°C at a rate of 0.3°C/sec while
continuously monitoring the fluorescent signal. Data
were analyzed by the standard software, SDS 2.3, and
RQ manager 1.2, included with the real-time PCR
system.
Western blot analysis
Total proteins were extracted from spleen, kidney, liver,
heart, pancreas, brain and some skeletal muscles dis-
sected from 12-week-old mice using RIPA buffer (50
mM Tris, pH 8, 150 mM NaCl, 0.1% SDS, 1% NP-40,
0.5% sodium deoxycholate, and protease inhibitors). The
Bradford assay was used to quantify protein concentra-
tions at A595nm. The proteins extracted from tissues (50
μg) were mixed with Laemmli loading buffer and heated
for 5 min at 95°C. The proteins were separated under
denaturating conditions into a 10% polyacrylamide gel
and then transferred to a Hybond C-Extra Nitrocellulose
membrane (Amersham Biosciences). Unspecific binding
was prevented using 5% non fat dry milk (w/v) in TBS-
T0.1% buffer (50 mM Tris, 150 mM NaCl, pH 7.4, 0.1%
Tween-20) for 1 h at room temperature. First antibodies
were diluted in 2% non fat dry milk in TBS-T0.1% buffer
[goat anti-GASP1 (AF2070, R&D Systems, 0.2 μg.ml-1);
rabbit anti-GASP1 (HPA010953, Sigma, 0.3 μg.ml-1);
rabbit anti-GASP1 directed against the peptide
DCGEEQTRWFDAQANN (0.9 μg.ml-1); goat anti-
GAPDH antibody (R&D Systems, 0.5 μg.ml-1)]. The
diluted antibodies were incubated with membrane over-
night at 4°C with constant agitation, followed by severalwashing steps in TBS-T0.1%. Blots were incubated with
the secondary antibodies, horseradish peroxidase-
coupled anti-goat IgG or anti-rabbit IgG (Dako) at a di-
lution of 1:2000 in 2% non fat dry milk in TBS-T0.1%
buffer for 1 h at RT. After several washing steps in TBS-
T0.1%, the immunoblots were processed by chemilumin-
escence detection (BM Chemiluminescence Western
Blotting Substrate (POD), Roche Applied Science) and
exposed to a film (Amersham Hyperfilm ECL, Amer-
sham Biosciences).
Statistical analysis
Unless indicated otherwise, data are presented as mean
± SEM. Data are considered significant with p < 0.05 by
two-tailed Student’s t test analysis.
Additional files
Additional file 1: Fiber type distribution in quadriceps of surGasp-1
mice. No significant variation in proportion of type I (dark grey) or type II
fibers (light grey) was observed in surGasp1-20, surGasp1-06 mice when
compared to wild-type. Data are expressed +/-SEM.
Additional file 2: Neonatal expression of Gasp-1 and myogenic
regulatory factors. mRNA expression levels were determined by qRT–
PCR relative to the reference genes Gapdh and TfIID in extracts from
head (dark grey, n = 3) or hindlimb (light grey, n = 3) of postnatal 3 days
surGasp1-20 animals. The horizontal dashed line represents a twofold
increase in expression level.* : p < 0.05 ; ** : p < 0.01.
Additional file 3: Table 1: List of the 96 genes that were measured on
the TaqMan Low Density Arrays.
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